Compare Stocks

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYAD Celyad Oncology	$0.60	$0.67	$0.46 ▼ $3.07	$15.91M	N/A	N/A	3,009 shs
HBPCF Helix BioPharma	$0.14	$0.14	$0.14 ▼ $0.15	$29.84M	-0.1	99 shs	N/A
MBRX Moleculin Biotech	$4.46 -3.7%	$7.26	$4.32 ▼ $24.75	$10.31M	1.96	85,366 shs	20,004 shs
OCUP Ocuphire Pharma	$1.76 -4.3%	$2.23	$1.71 ▼ $6.60	$45.66M	0.34	266,482 shs	196,987 shs
PVOTF BetterLife Pharma	$0.13 -4.7%	$0.13	$0.03 ▼ $0.38	$21.70M	N/A	52,703 shs	198,200 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYAD Celyad Oncology	0.00%	0.00%	0.00%	0.00%	-27.27%
HBPCF Helix BioPharma	0.00%	0.00%	-2.55%	-5.03%	-5.81%
MBRX Moleculin Biotech	-3.61%	-11.68%	-39.87%	-54.92%	-67.33%
OCUP Ocuphire Pharma	-4.35%	-3.83%	-7.37%	-39.93%	-67.16%
PVOTF BetterLife Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Trump’s “Tax Free” Retirement Strategy (Ad)

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	2.2878 of 5 stars	3.5	3.0	0.0	0.0	2.9	0.0	1.3
OCUP Ocuphire Pharma	2.395 of 5 stars	3.5	2.0	0.0	0.0	2.6	1.7	1.3
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYAD Celyad Oncology	N/A	N/A	N/A	N/A
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	3.00	Buy	$35.00	684.75% Upside
OCUP Ocuphire Pharma	3.00	Buy	$19.00	979.55% Upside
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest MBRX, HBPCF, OCUP, PVOTF, and CYAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/12/2024	MBRX Moleculin Biotech	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/26/2024	MBRX Moleculin Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $20.00
3/20/2024	OCUP Ocuphire Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $20.00

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYAD Celyad Oncology	$110K	144.65	N/A	N/A	$0.20 per share	3.00
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$11.70 per share	N/A
OCUP Ocuphire Pharma	$19.05M	2.29	N/A	N/A	$2.20 per share	0.80
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYAD Celyad Oncology	-$9.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HBPCF Helix BioPharma	-$4.69M	-$0.04	N/A	∞	N/A	N/A	-817.64%	-308.71%	6/12/2024 (Estimated)
MBRX Moleculin Biotech	-$29.77M	-$13.64	N/A	N/A	N/A	N/A	-80.91%	-67.69%	5/9/2024 (Estimated)
OCUP Ocuphire Pharma	-$9.99M	-$0.48	N/A	N/A	N/A	-52.42%	-22.30%	-20.27%	5/20/2024 (Estimated)
PVOTF BetterLife Pharma	-$14.78M	N/A	N/A	∞	N/A	N/A	-205.15%	-147.23%	N/A

Latest MBRX, HBPCF, OCUP, PVOTF, and CYAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/8/2024	Q4 2023	OCUP Ocuphire Pharma	-$0.07	-$0.21	-$0.14	-$0.21	$3.47 million	$1.69 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYAD Celyad Oncology	N/A	N/A	N/A
HBPCF Helix BioPharma	N/A	1.46	1.46
MBRX Moleculin Biotech	N/A	3.86	3.86
OCUP Ocuphire Pharma	N/A	13.35	13.35
PVOTF BetterLife Pharma	N/A	3.62	3.62

Ownership

Institutional Ownership

Company	Institutional Ownership
CYAD Celyad Oncology	N/A
HBPCF Helix BioPharma	N/A
MBRX Moleculin Biotech	15.52%
OCUP Ocuphire Pharma	14.97%
PVOTF BetterLife Pharma	N/A

Insider Ownership

Company	Insider Ownership
CYAD Celyad Oncology	0.94%
HBPCF Helix BioPharma	7.60%
MBRX Moleculin Biotech	6.70%
OCUP Ocuphire Pharma	8.70%
PVOTF BetterLife Pharma	34.77%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CYAD Celyad Oncology	95	26.52 million	26.28 million	Not Optionable
HBPCF Helix BioPharma	9	216.67 million	200.21 million	Not Optionable
MBRX Moleculin Biotech	15	2.23 million	2.08 million	Not Optionable
OCUP Ocuphire Pharma	14	24.81 million	22.65 million	Optionable
PVOTF BetterLife Pharma	N/A	171.41 million	N/A	Not Optionable

MBRX, HBPCF, OCUP, PVOTF, and CYAD Headlines

Source	Headline
	Vertex Pharma scientist talks about the long road to developing non-addictive painkillers abcnews.go.com - April 15 at 12:36 PM
	Pharmacy defends Eli Lilly off-label drug suit lifesciencesipreview.com - April 11 at 2:26 PM
	BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference tmcnet.com - April 11 at 9:26 AM
	Victory Over Big Pharma Will Take More Than the IRA msn.com - April 4 at 8:20 PM
	Liberals Need to Be Radicals prospect.org - April 4 at 10:19 AM
	Pharma is betting big on connecting potential patients to its medications. It's just the beginning endpts.com - April 3 at 2:37 AM
	AEVIS VICTORIA SA - Fabrice Zumbrunnen to become… pharmiweb.com - March 13 at 4:50 AM
	Presence of Particulates Prompts Recall of Treprostinil Injection empr.com - March 13 at 4:50 AM
	In Vietnam’s Mekong Delta, the lure of moving to the city grows even stronger amid climate shocks kdvr.com - March 12 at 10:24 PM
	America’s Last Top Models newyorker.com - March 12 at 10:24 PM
	Profile: Xi Jinping the reformer chinadaily.com.cn - March 12 at 12:23 PM
	BetterLife Pharma Inc.: BetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University finanznachrichten.de - March 4 at 1:49 PM
	India continues fast economic growth but FDI falls sharply global.chinadaily.com.cn - March 1 at 8:26 AM
	GenesisCare Completes Reorganisation and Emerges from Chapter 11 pharmiweb.com - February 19 at 3:51 PM
	Immigrant Execs Give Back to OC ocbj.com - February 5 at 9:25 PM
	The tragedy of Leonard Farruku, the gifted young musician whose dream of a better life ended on the Bibby Stockholm theguardian.com - February 5 at 9:25 PM
	Weight loss drugs could create the first $1 trillion pharma companies msn.com - February 1 at 9:57 AM
	Roff: Medicare prescription price controls will hurt seniors news-journal.com - January 31 at 11:57 PM
	Budget 2024 Live Updates: Infrastructure, income tax, fiscal deficit, job creation announcements expected from FM Sitharaman's Union Budget timesofindia.indiatimes.com - January 31 at 11:57 PM
	BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001 finance.yahoo.com - January 2 at 10:19 AM
	Big Pharma scrambles to feed demand for weight-loss treatments amid rising U.S. obesity rates nbcnewyork.com - November 16 at 5:01 PM
	Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates msn.com - November 16 at 12:01 PM
	US Patent and Trademark Office Publishes BetterLife's Comprehensive Patent for BETR-001 and Other LSD Derivatives tmcnet.com - November 15 at 12:13 PM
	MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749) businesswire.com - November 13 at 2:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Celyad Oncology

NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Helix BioPharma

OTCMKTS:HBPCF

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Moleculin Biotech

NASDAQ:MBRX

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Ocuphire Pharma

NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

BetterLife Pharma

OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial